Vertex Pharma To Acquire ViaCyte For $320 Mln In Cash

Vertex Advances Inaxaplin Into Phase 2/3 Trial To Treat APOL1-Mediated Kidney Disease

Vertex Pharmaceuticals Inc. (VRTX) announced Monday that inaxaplin (VX-147) has advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in APOL1-mediated kidney disease (AMKD), where a 45 mg once daily oral dose will be compared to placebo, on top of standard of care.

RTTNews | 333日前

Vertex Receives CHMP Positive Opinion For The First CRISPR/Cas9 Gene-Edited Therapy CASGEVY

Vertex Pharmaceuticals Inc. (VRTX) announced Friday that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the conditional approval of CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited therapy, for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

RTTNews | 441日前

Vertex Pharma Inks Licensing Agreement To Use CRISPR Therapeutics' Gene Editing Technology

Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) and gene editing company CRISPR Therapeutics, Inc. (CRSP) announced Monday that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics' gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex's hypoimmune cell therapies for type 1 diabetes (T1D).

RTTNews | 704日前

Vertex Pharma Says FDA Lifts Clinical Hold On Phase 1/2 Trial Of VX-880 To Treat Type 1 Diabetes

Vertex Pharmaceuticals Inc. (VRTX) announced Tuesday that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1/2 clinical trial of VX-880, an investigational stem cell-derived, fully differentiated pancreatic islet cell replacement therapy for people with type 1 diabetes (T1D) with impaired hypoglycemic awareness and severe hypoglycemia.

RTTNews | 969日前

TSX Ends More Than 1% Up

After a weak start and a subsequent recovery, the Canadian market slipped into negative territory around early afternoon on Friday, but gained in strength after that with stocks from industrials, financials, utilities and consumer staples attracting buyers.

RTTNews | 11時8分前

Dollar Rises Against Major Counterparts

The U.S. dollar climbed higher on Friday, extending gains from the previous session following U.S. President Donald Trump's announcement that the 25% tariffs on Canada and Mexico, and an additional 10% on China, will take effect early next week.

RTTNews | 11時42分前

German Inflation Steady At 2.3% In February

Consumer price inflation in Germany was unchanged in February, while the core price growth slowed as the cost of food increased strongly, preliminary data from the statistical office Destatis showed on Friday.

RTTNews | 14時9分前

Canadian Market Modestly Higher In Cautious Trade

The Canadian benchmark S&P/TSX Composite Index is modestly higher in late afternoon trades on Friday with stocks turning in a mixed performance. Worries about U.S. tariffs and their potential impact on global economic growth appear to be weighing on sentiment. Investors are also digesting the nation's GDP report and U.S. PCE reading.

RTTNews | 14時23分前

EURUSD	1.03732	GBPUSD	1.25787	AUDUSD	0.6204
USDJPY	150.505	USDCAD	1.44707	USDCHF	0.90292